STable2 Hierarchical analysis of correlation between LMR and OS in lung cancer patients

	No. of studies	Combined HR (95% CI)	P value	$P_{interaction}$ value	Heterogeneity P	Heterogeneity I^2	Residual heterogeneity
Total OS	23	1.61 (1.45, 1.79)	<0.01	—	0.01	46%	—
Histology							30%
NSCLC	20	1.69 (1.52, 1.88)	<0.01		0.13	27%	
SCLC	2	1.21 (0.87, 1.67)	0.25	0.12	0.12	59%	
NSCLC and SCLC	1	1.51 (1.26, 1.80)	<0.01		—	—	
Tumor stage							14%
ED	11	1.89 (1.64, 2.17)	<0.01		0.68	0%	
LD	9	1.53 (1.39, 1.69)	<0.01	<0.01	0.12	38%	
LD and ED	3	1.19 (1.01, 1.40)	0.06		0.22	34%	
Treatment							24%
Chemotherapy	6	1.77 (1.50, 2.09)	<0.01		0.54	0%	
TKI	2	1.80 (0.87, 3.70)	0.11		0.24	28%	
SABR	1	1.84 (1.01, 3.34)	0.05		—	—	
Chemotherapy+TKI	1	2.49 (1.72, 3.60)	<0.01	0.03	—	—	
Surgery	7	1.58 (1.29, 1.94)	<0.01		0.05	52%	
Chemotherapy+Radiotherapy	3	1.22 (0.99, 1.50)	0.06		0.22	34%	
Immunology	3	1.71 (1.27, 2.31)	<0.01		0.91	0%	
Sample size							41%
>300	10	1.48 (1.31, 1.67)	<0.01	0.06	0.04	49%	
<300	13	1.80 (1.53, 2.13)	<0.01		0.12	33%	
Cut-off value							45%
>4	8	1.69 (1.41, 2.03)	<0.01	0.48	0.10	41%	
<4	15	1.56 (1.37, 1.78)	<0.01		0.02	47%	